Sample Prescription for Alprostadil
For erectile dysfunction, alprostadil must be initiated under direct healthcare provider supervision with in-office dose titration before any home prescription is written. 1
Intracavernosal Injection (Most Effective Non-Surgical Option)
Initial In-Office Protocol:
- Start with 2.5 mcg intracavernosal injection in the office 2
- Escalate through 5,10,15,20,30, up to 40 mcg maximum until optimal response achieved (erection sufficient for penetration lasting 30-60 minutes) 2
- Monitor for 10 minutes post-injection for syncope, hypotension, and prolonged erection 1
- Demonstrate proper injection technique to patient before prescribing for home use 1
- Mean optimal dose in clinical studies was approximately 11.9 mcg 2
Sample Home Prescription (after in-office titration):
Alprostadil for injection [dose determined in office, typically 10-20 mcg]
Inject intracavernosally as demonstrated
Use no more than once per 24-hour period
Dispense: [quantity for 1-3 months]
Refills: [as appropriate]Critical Safety Instructions to Patient:
- Seek immediate medical attention for erections lasting >4 hours 1
- For erections <4 hours but prolonged, intracavernosal phenylephrine is first-line treatment 3, 1
- Maximum frequency: once per 24 hours 1
Intraurethral Alprostadil (MUSE) - Second-Line Alternative
Initial Dosing:
- Start with 500 mcg intraurethral pellet (higher efficacy than 250 mcg with minimal difference in adverse events) 4
- First dose must be administered in-office to assess response 5
- Can escalate to 1000 mcg if needed; 65% of patients ultimately use 1000 mcg dose 5
Sample Prescription:
Alprostadil urethral suppository 500 mcg (or 1000 mcg after titration)
Insert one pellet intraurethrally 5-10 minutes before intercourse
Use no more than twice weekly
Dispense: [quantity for 1-3 months]
Refills: [as appropriate]Efficacy Expectations:
- 65.9% of men achieve erections sufficient for intercourse in clinic testing 6
- 64.9% successfully complete intercourse at home vs. 18.6% with placebo 6
- Onset of erection averages 11.2 minutes; duration averages 50.5 minutes 2
- After prostate cancer surgery, efficacy is lower (53.9% very good/good response) 5
Topical Alprostadil Cream - Alternative Formulation
Dosing Protocol:
- Initial dose: 200 mcg applied to penile meatus 7
- Adjust to 300 mcg if hypo-responsive (73% of patients ultimately select this dose) 7
- Maximum 2 doses per week for first 4 weeks, then up to 2 doses per week ongoing 7
Sample Prescription:
Alprostadil cream 300 mcg
Apply to penile meatus as directed before intercourse
Use no more than twice weekly
Dispense: [quantity for 1-3 months]
Refills: [as appropriate]Treatment Algorithm Selection
First-line: PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) 1
Second-line (after PDE5i failure):
- Intracavernosal injection if patient accepts injection and desires most effective non-surgical option 1
- Intraurethral alprostadil if patient prefers to avoid injection 4, 5
- Topical alprostadil if patient prefers non-invasive application 7
Combination therapy: Topical alprostadil plus PDE5i shows superior efficacy (IIEF-5 increased from 12.4 to 17.1) compared to topical alprostadil alone in PDE5i non-responders 8
Common Adverse Events and Management
Intracavernosal:
- Penile pain (6%) 2
- Risk of penile fibrosis with chronic use (requires 3-month follow-up monitoring) 3
- Priapism risk <1% but requires clear action plan 1
Intraurethral:
- Penile pain (10.8% of administrations) 6
- Hypotension (3.3% in clinic, uncommon at home) 6
- No priapism or fibrosis reported 6
Topical:
- Application site burning/erythema (12.2%) 7
- Meatal/glans pain (4.4%) 7
- Prolonged erection ≥4 hours (0.4%) 7
- Partner vaginal burning/itching (2.1%) 7